Retaglutide is a novel GLP-1 receptor agonist currently under research for the treatment of metabolic disorders. This therapy works by enhancing the effects of glucagon-like peptide-1 (GLP-1), a naturally occurring https://hassanqjpy188902.ssnblog.com/37755049/trelaglutide-exploring-a-new-option-for-chronic-diseases